We demonstrated that HNRNPC facilitates glioma progression and helps maintain the mRNA stability of interleukin-1 receptor-associated kinase 1 (IRAK1) in an m6A-dependent manner, resulting in activation of the mitogen-activated protein kinase (MAPK) signaling pathway. Here, IRAK1 is linked to central nervous system cancer.